| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | 179 | $696M | +$75.4M | -$67.5M | +$7.9M | EMR, GLW, IBM, TSM, OGE | 13F-HR | 11/8/2024, 04:00 PM |
| Q2 2024 | 179 | $655M | +$41.4M | -$33.2M | +$8.23M | EMR, GLW, TSM, IBM, OGE | 13F-HR | 8/8/2024, 02:46 PM |
| Q1 2024 | 174 | $652M | +$25.9M | -$47.5M | -$21.5M | EMR, GLW, IBM, TSM, OGE | 13F-HR | 5/6/2024, 12:01 PM |
| Q4 2023 | 169 | $630M | +$45.8M | -$66.5M | -$20.7M | EMR, GLW, IBM, OGE, BMY | 13F-HR | 1/31/2024, 01:44 PM |
| Q3 2023 | 173 | $611M | +$16.7M | -$27.5M | -$10.9M | EMR, GLW, BMY, CSCO, PFE | 13F-HR | 11/1/2023, 03:28 PM |
| Q2 2023 | 177 | $648M | +$32.5M | -$35.7M | -$3.22M | EMR, GLW, BMY, PFE, OGE | 13F-HR | 8/21/2023, 09:27 AM |
| Q1 2023 | 177 | $643M | +$40M | -$26.9M | +$13.1M | EMR, GLW, BMY, PFE, OGE | 13F-HR | 5/5/2023, 02:01 PM |
| Q4 2022 | 169 | $627M | +$25.8M | -$48.9M | -$23.1M | EMR, PFE, BMY, GLW, XOM | 13F-HR | 2/8/2023, 12:01 PM |
| Q3 2022 | 157 | $572M | +$41.9M | -$43.7M | -$1.74M | EMR, BMY, PFE, GLW, OGE | 13F-HR | 10/19/2022, 11:00 AM |
| Q2 2022 | 157 | $623M | +$40.1M | -$65M | -$24.9M | PFE, EMR, BMY, OGE, GLW | 13F-HR | 7/27/2022, 01:43 PM |
| Q1 2022 | 168 | $721M | +$33.9M | -$26.3M | +$7.56M | EMR, PFE, OGE, BMY, GLW | 13F-HR | 4/29/2022, 10:12 AM |
| Q4 2021 | 162 | $727M | +$27.5M | -$79.7M | -$52.2M | PFE, EMR, OGE, CSCO, BMY | 13F-HR | 1/26/2022, 01:55 PM |
| Q3 2021 | 159 | $735M | +$34.8M | -$42.5M | -$7.69M | EMR, PFE, OGE, VZ, GLW | 13F-HR | 11/2/2021, 01:49 PM |
| Q2 2021 | 156 | $768M | +$37.8M | -$35.8M | +$2M | EMR, OGE, BMY, PFE, GLW | 13F-HR | 7/23/2021, 11:18 AM |
| Q1 2021 | 154 | $745M | +$73.6M | -$37.8M | +$35.8M | EMR, GLW, BMY, INTC, PFE | 13F-HR | 4/22/2021, 03:08 PM |
| Q4 2020 | 152 | $645M | +$119M | -$16.2M | +$103M | EMR, BMY, GLW, PFE, INTC | 13F-HR | 2/5/2021, 01:42 PM |
| Q3 2020 | 128 | $483M | +$62.6M | -$9.85M | +$52.8M | EMR, BMY, GLW, PFE, INTC | 13F-HR | 11/6/2020, 10:31 AM |
| Q2 2020 | 109 | $410M | +$32.4M | -$50.2M | -$17.8M | EMR, BMY, PFE, GLW, GSK | 13F-HR | 7/29/2020, 01:56 PM |
| Q1 2020 | 100 | $377M | +$28.2M | -$116M | -$87.5M | EMR, BMY, GLW, PFE, GSK | 13F-HR | 4/14/2020, 01:18 PM |
| Q4 2019 | 142 | $581M | +$29.3M | -$39M | -$9.73M | EMR, BMY, GLW, PFE, XOM | 13F-HR | 1/29/2020, 02:34 PM |
| Q3 2019 | 144 | $551M | +$43.8M | -$48.2M | -$4.4M | EMR, XOM, GLW, BMY, PFE | 13F-HR | 10/21/2019, 02:07 PM |
| Q2 2019 | 148 | $569M | +$54.8M | -$44.7M | +$10.1M | EMR, XOM, GVA, GLW, PFE | 13F-HR | 8/2/2019, 02:11 PM |
| Q1 2019 | 128 | $552M | +$30.4M | -$30.6M | -$155K | EMR, XOM, GVA, GLW, PFE | 13F-HR | 4/30/2019, 02:49 PM |
| Q4 2018 | 129 | $496M | +$56.6M | -$43M | +$13.6M | EMR, XOM, GLW, PFE, GVA | 13F-HR | 1/29/2019, 01:01 PM |
| Q3 2018 | 129 | $550M | +$33.5M | -$42.5M | -$9.01M | XOM, EMR, GLW, PFE, MRK | 13F-HR | 11/2/2018, 02:46 PM |
| Q2 2018 | 114 | $529M | +$33.7M | -$27.2M | +$6.48M | XOM, EMR, JNJ, GLW, SLB | 13F-HR | 7/23/2018, 01:53 PM |
| Q1 2018 | 114 | $517M | +$44.2M | -$22.8M | +$21.3M | XOM, EMR, JNJ, GLW, SLB | 13F-HR | 4/19/2018, 02:49 PM |
| Q4 2017 | 114 | $501M | +$24.4M | -$57M | -$32.6M | EMR, XOM, JNJ, GLW, SLB | 13F-HR | 1/31/2018, 09:48 AM |
| Q3 2017 | 108 | $513M | +$28.7M | -$40.6M | -$11.9M | XOM, JNJ, EMR, GLW, PFE | 13F-HR | 11/3/2017, 09:50 AM |
| Q2 2017 | 113 | $504M | +$38.3M | -$28.9M | +$9.4M | JNJ, GLW, XOM, EMR, PFE | 13F-HR | 7/26/2017, 03:58 PM |
| Q1 2017 | 116 | $484M | +$30.3M | -$44.6M | -$14.3M | JNJ, GLW, XOM, EMR, PFE | 13F-HR | 4/25/2017, 02:48 PM |
| Q4 2016 | 119 | $477M | +$24.2M | -$47.6M | -$23.4M | JNJ, GLW, EMR, XOM, PFE | 13F-HR | 1/20/2017, 04:22 PM |
| Q3 2016 | 115 | $486M | +$27.6M | -$44.1M | -$16.4M | JNJ, GLW, EMR, XOM, PFE | 13F-HR | 10/20/2016, 02:50 PM |
| Q2 2016 | 116 | $487M | +$49.7M | -$12.3M | +$37.4M | JNJ, GLW, XOM, EMR, PFE | 13F-HR | 7/22/2016, 08:30 AM |
| Q1 2016 | 104 | $426M | +$30.6M | -$79.1M | -$48.5M | JNJ, GLW, XOM, EMR, GVA | 13F-HR | 4/27/2016, 12:27 PM |
| Q4 2015 | 114 | $453M | +$40.8M | -$37.7M | +$3.09M | JNJ, GLW, KO, XOM, EMR | 13F-HR | 2/11/2016, 12:27 PM |
| Q3 2015 | 121 | $421M | +$37M | -$105M | -$68M | JNJ, GLW, KO, XOM, PFE | Restatement | 10/23/2015, 10:26 AM |
| Q2 2015 | 144 | $531M | +$37.3M | -$28.8M | +$8.55M | JNJ, GLW, XOM, EMR, KO | 13F-HR | 8/11/2015, 11:03 AM |
| Q1 2015 | 141 | $526M | +$32.5M | -$29.8M | +$2.73M | JNJ, GLW, XOM, EMR, KO | 13F-HR | 5/13/2015, 12:56 PM |
| Q4 2014 | 145 | $531M | +$32.4M | -$45M | -$12.6M | JNJ, GLW, XOM, EMR, KO | 13F-HR | 1/26/2015, 02:34 PM |
| Q3 2014 | 148 | $520M | +$24.7M | -$40.8M | -$16.1M | JNJ, XOM, GLW, EMR, KO | 13F-HR | 11/12/2014, 10:39 AM |
| Q2 2014 | 152 | $548M | +$24.6M | -$32.6M | -$7.93M | JNJ, GLW, XOM, EMR, KO | 13F-HR | 7/18/2014, 03:23 PM |
| Q1 2014 | 147 | $540M | +$30M | -$30.8M | -$738K | JNJ, GLW, XOM, EMR, KO | 13F-HR | 5/7/2014, 10:03 AM |
| Q4 2013 | 149 | $524M | $0 | $0 | JNJ, XOM, GLW, EMR, KO | 13F-HR | 2/3/2014, 01:09 PM |